An open-label, randomized, single dose, two period, crossover study to determine the bioequivalence between valsartan 160 mg pediatric final market image (FMI) formulation (solution) and clinical service form (CSF) of valsartan 160 mg extemporaneous suspension in healthy adult volunteers.
Latest Information Update: 29 Jul 2024
Price :
$35 *
At a glance
- Drugs Valsartan (Primary)
- Indications Essential hypertension; Heart failure; Hypertension; Postmyocardial infarction
- Focus Pharmacokinetics
- Sponsors Novartis
- 28 Mar 2018 Status changed to completed.
- 22 Aug 2017 New trial record